Kết quả tìm kiếm - Tebbutt, Niall C

Tinh chỉnh kết quả
  1. 1
    Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature

    Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature Bằng Chan, David L., Pavlakis, Nick, Shapiro, Jeremy, Price, Timothy J., Karapetis, Christos S., Tebbutt, Niall C., Segelov, Eva

    Được phát hành 2015
    lấy văn bản lấy văn bản lấy văn bản
    Text
    Lưu vào danh sách
    Đã lưu trong:
  2. 2
    Correction: Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature

    Correction: Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature Bằng Chan, David L., Pavlakis, Nick, Shapiro, Jeremy, Price, Timothy J., Karapetis, Christos S., Tebbutt, Niall C., Segelov, Eva

    Được phát hành 2015
    lấy văn bản lấy văn bản lấy văn bản
    Text
    Lưu vào danh sách
    Đã lưu trong:
  3. 3
    Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis From Seven Randomized Controlled Trials

    Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis From Seven Randomized Controlled Trials Bằng Hurwitz, Herbert I., Tebbutt, Niall C., Kabbinavar, Fairooz, Giantonio, Bruce J., Guan, Zhong-Zhen, Mitchell, Lada, Waterkamp, Daniel, Tabernero, Josep

    Được phát hành 2013
    lấy văn bản lấy văn bản lấy văn bản
    Text
    Lưu vào danh sách
    Đã lưu trong:
  4. 4
    Severe combined hyperlipidaemia and retinal lipid infiltration in a patient with Type 2 diabetes mellitus

    Severe combined hyperlipidaemia and retinal lipid infiltration in a patient with Type 2 diabetes mellitus Bằng Davey, Rachel A, Tebbutt, Niall C, Favaloro, Jenny M, O'Neal, David N, Rae, Derek, Zajac, Jeffrey D, Best, James D

    Được phát hành 2006
    lấy văn bản lấy văn bản lấy văn bản
    Text
    Lưu vào danh sách
    Đã lưu trong:
  5. 5
    A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction

    A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction Bằng Shah, Manish A., Cho, Jae-Yong, Tan, Iain B., Tebbutt, Niall C., Yen, Chia-Jui, Kang, Alice, Shames, David S., Bu, Lilian, Kang, Yoon-Koo

    Được phát hành 2016
    lấy văn bản lấy văn bản lấy văn bản
    Text
    Lưu vào danh sách
    Đã lưu trong:
  6. 6
    K‐Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines

    K‐Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines Bằng Yeung, Yvonne, Lau, David K., Chionh, Fiona, Tran, Hoanh, Tse, Janson W. T., Weickhardt, Andrew J., Nikfarjam, Mehrdad, Scott, Andrew M., Tebbutt, Niall C., Mariadason, John M.

    Được phát hành 2017
    lấy văn bản lấy văn bản lấy văn bản
    Text
    Lưu vào danh sách
    Đã lưu trong:
  7. 7
    Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study

    Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study Bằng Lau, David K., Tay, Rebecca Y., Yeung, Yvonne H., Chionh, Fiona, Mooi, Jennifer, Murone, Carmel, Skrinos, Effie, Price, Timothy J., Mariadason, John M., Tebbutt, Niall C.

    Được phát hành 2018
    lấy văn bản lấy văn bản lấy văn bản
    Text
    Lưu vào danh sách
    Đã lưu trong:
  8. 8
    Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab*

    Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab* Bằng Price, Timothy J, Hardingham, Jennifer E, Lee, Chee K, Townsend, Amanda R, Wrin, Joseph W, Wilson, Kate, Weickhardt, Andrew, Simes, Robert J, Murone, Carmel, Tebbutt, Niall C

    Được phát hành 2013
    lấy văn bản lấy văn bản lấy văn bản
    Text
    Lưu vào danh sách
    Đã lưu trong:
  9. 9
    The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT]

    The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT] Bằng Clarke, Stephen John, Burge, Matthew, Feeney, Kynan, Gibbs, Peter, Jones, Kristian, Marx, Gavin, Molloy, Mark P., Price, Timothy, Reece, William H. H., Segelov, Eva, Tebbutt, Niall C.

    Được phát hành 2020
    lấy văn bản lấy văn bản lấy văn bản
    Text
    Lưu vào danh sách
    Đã lưu trong:
  10. 10
    Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial

    Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial Bằng Klein, Oliver, Kee, Damien, Nagrial, Adnan, Markman, Ben, Underhill, Craig, Michael, Michael, Jackett, Louise, Lum, Caroline, Behren, Andreas, Palmer, Jodie, Tebbutt, Niall C., Carlino, Matteo S., Cebon, Jonathan

    Được phát hành 2020
    lấy văn bản lấy văn bản lấy văn bản
    Text
    Lưu vào danh sách
    Đã lưu trong:
  11. 11
    Glycoprotein A33 deficiency: a new mouse model of impaired intestinal epithelial barrier function and inflammatory disease

    Glycoprotein A33 deficiency: a new mouse model of impaired intestinal epithelial barrier function and inflammatory disease Bằng Williams, Benjamin B., Tebbutt, Niall C., Buchert, Michael, Putoczki, Tracy L., Doggett, Karen, Bao, Shisan, Johnstone, Cameron N., Masson, Frederick, Hollande, Frederic, Burgess, Antony W., Scott, Andrew M., Ernst, Matthias, Heath, Joan K.

    Được phát hành 2015
    lấy văn bản lấy văn bản lấy văn bản
    Text
    Lưu vào danh sách
    Đã lưu trong:
  12. 12
    The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors

    The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors Bằng Rosen, Lee S, Lipton, Lara, Price, Timothy J, Belman, Neil D, Boccia, Ralph V, Hurwitz, Herbert I, Stephenson Jr, Joe J, Wirth, Lori J, McCoy, Sheryl, Hei, Yong-jiang, Hsu, Cheng-Pang, Tebbutt, Niall C

    Được phát hành 2013
    lấy văn bản lấy văn bản lấy văn bản
    Text
    Lưu vào danh sách
    Đã lưu trong:
  13. 13
    Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial

    Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial Bằng Tebbutt, Niall C, Price, Timothy J, Ferraro, Danielle A, Wong, Nicole, Veillard, Anne-Sophie, Hall, Merryn, Sjoquist, Katrin M, Pavlakis, Nick, Strickland, Andrew, Varma, Suresh C, Cooray, Prasad, Young, Rosemary, Underhill, Craig, Shannon, Jennifer A, Ganju, Vinod, Gebski, Val

    Được phát hành 2016
    lấy văn bản lấy văn bản lấy văn bản
    Text
    Lưu vào danh sách
    Đã lưu trong:
  14. 14
    DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis

    DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis Bằng Tögel, Lars, Nightingale, Rebecca, Wu, Rui, Chüeh, Anderly C., Al-Obaidi, Sheren, Luk, Ian, Dávalos-Salas, Mercedes, Chionh, Fiona, Murone, Carmel, Buchanan, Daniel D., Chatterton, Zac, Sieber, Oliver M., Arango, Diego, Tebbutt, Niall C., Williams, David, Dhillon, Amardeep S., Mariadason, John M.

    Được phát hành 2018
    lấy văn bản lấy văn bản lấy văn bản
    Text
    Lưu vào danh sách
    Đã lưu trong:
  15. 15
    Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer

    Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer Bằng Cutsem, Eric Van, Eng, Cathy, Nowara, Elzbieta, Świeboda-Sadlej, Anna, Tebbutt, Niall C., Mitchell, Edith, Davidenko, Irina, Stephenson, Joe, Elez, Elena, Prenen, Hans, Deng, Hongjie, Tang, Rui, McCaffery, Ian, Oliner, Kelly S., Chen, Lisa, Gansert, Jennifer, Loh, Elwyn, Smethurst, Dominic, Tabernero, Josep

    Được phát hành 2014
    lấy văn bản lấy văn bản lấy văn bản
    Text
    Lưu vào danh sách
    Đã lưu trong:
  16. 16
    Phase I Biodistribution and Pharmacokinetic Study of Lewis Y–Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers

    Phase I Biodistribution and Pharmacokinetic Study of Lewis Y–Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers Bằng Herbertson, Rebecca A., Tebbutt, Niall C., Lee, Fook-Thean, MacFarlane, David J., Chappell, Bridget, Micallef, Noel, Lee, Sze-Ting, Saunder, Timothy, Hopkins, Wendie, Smyth, Fiona E., Wyld, David K., Bellen, John, Sonnichsen, Daryl S., Brechbiel, Martin W., Murone, Carmel, Scott, Andrew M.

    Được phát hành 2009
    lấy văn bản lấy văn bản lấy văn bản
    Text
    Lưu vào danh sách
    Đã lưu trong:
  17. 17
    VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer

    VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer Bằng Chionh, Fiona, Gebski, Val, Al-Obaidi, Sheren J., Mooi, Jennifer K., Bruhn, Maressa A., Lee, Chee K., Chüeh, Anderly C., Williams, David S., Weickhardt, Andrew J., Wilson, Kate, Scott, Andrew M., Simes, John, Hardingham, Jennifer E., Price, Timothy J., Mariadason, John M., Tebbutt, Niall C.

    Được phát hành 2022
    lấy văn bản lấy văn bản lấy văn bản
    Text
    Lưu vào danh sách
    Đã lưu trong:
  18. 18
    RHOA inactivation enhances Wnt signaling and promotes colorectal cancer

    RHOA inactivation enhances Wnt signaling and promotes colorectal cancer Bằng Rodrigues, Paulo, Macaya, Irati, Bazzocco, Sarah, Mazzolini, Rocco, Andretta, Elena, Dopeso, Higinio, Mateo-Lozano, Silvia, Bilić, Josipa, Cartón-García, Fernando, Nieto, Rocio, Suárez-López, Lucia, Afonso, Elsa, Landolfi, Stefania, Hernandez-Losa, Javier, Kobayashi, Kazuto, Cajal, Santiago Ramón y, Tabernero, Josep, Tebbutt, Niall C., Mariadason, John M., Schwartz, Simo, Arango, Diego

    Được phát hành 2014
    lấy văn bản lấy văn bản lấy văn bản
    Text
    Lưu vào danh sách
    Đã lưu trong:
  19. 19
    Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial

    Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, dou... Bằng Catenacci, Daniel V T, Tebbutt, Niall C, Davidenko, Irina, Murad, André M, Al-Batran, Salah-Eddin, Ilson, David H, Tjulandin, Sergei, Gotovkin, Evengy, Karaszewska, Boguslawa, Bondarenko, Igor, Tejani, Mohamedtaki A, Udrea, Anghel A, Tehfe, Mustapha, De Vita, Ferdinando, Turkington, Cheryl, Tang, Rui, Ang, Agnes, Zhang, Yilong, Hoang, Tien, Sidhu, Roger, Cunningham, David

    Được phát hành 2017
    lấy văn bản lấy văn bản lấy văn bản
    Text
    Lưu vào danh sách
    Đã lưu trong:
  20. 20
    Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study

    Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study Bằng Ohtsu, Atsushi, Ajani, Jaffer A., Bai, Yu-Xian, Bang, Yung-Jue, Chung, Hyun-Cheol, Pan, Hong-Ming, Sahmoud, Tarek, Shen, Lin, Yeh, Kun-Huei, Chin, Keisho, Muro, Kei, Kim, Yeul Hong, Ferry, David, Tebbutt, Niall C., Al-Batran, Salah-Eddin, Smith, Heind, Costantini, Chiara, Rizvi, Syed, Lebwohl, David, Van Cutsem, Eric

    Được phát hành 2013
    lấy văn bản lấy văn bản lấy văn bản
    Text
    Lưu vào danh sách
    Đã lưu trong:

Công cụ tìm kiếm: